Symbols / ALT $2.91 -3.68% Altimmune, Inc.

Healthcare • Biotechnology • United States • NGM
ALT Chart
About

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 378.46M
Enterprise Value 155.04M Income -88.09M Sales 41.00K
Book/sh 2.03 Cash/sh 2.10 Dividend Yield —
Payout 0.00% Employees 57 IPO —
P/E — Forward P/E -2.13 PEG —
P/S 9230.80 P/B 1.43 P/C —
EV/EBITDA -1.64 EV/Sales 3781.55 Quick Ratio 18.35
Current Ratio 18.55 Debt/Eq 15.87 LT Debt/Eq —
EPS (ttm) -1.00 EPS next Y -1.36 EPS Growth —
Revenue Growth 4.20% Earnings 2026-05-12 ROA -28.17%
ROE -50.57% ROIC — Gross Margin 0.00%
Oper. Margin -1111.27% Profit Margin 0.00% Shs Outstand 130.11M
Shs Float 129.18M Short Float 20.39% Short Ratio 8.53
Short Interest — 52W High 7.73 52W Low 2.90
Beta 0.17 Avg Volume 4.62M Volume 1.85M
Target Price $18.00 Recom Buy Prev Close $3.02
Price $2.91 Change -3.68%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$18.00
Mean price target
2. Current target
$2.88
Latest analyst target
3. DCF / Fair value
$-5.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.88
Low
$1.00
High
$28.00
Mean
$18.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-16 main HC Wainwright & Co. Buy → Buy $25
2026-03-06 main B. Riley Securities Buy → Buy $13
2025-11-07 main Citizens Market Outperform → Market Outperform $14
2025-10-20 reit HC Wainwright & Co. Buy → Buy $12
2025-10-10 reit HC Wainwright & Co. Buy → Buy $12
2025-08-13 reit HC Wainwright & Co. Buy → Buy $12
2025-08-13 main UBS Buy → Buy $24
2025-08-13 main B. Riley Securities Buy → Buy $18
2025-07-10 main JMP Securities Market Outperform → Market Outperform $15
2025-06-27 reit HC Wainwright & Co. Buy → Buy $12
2025-04-03 reit HC Wainwright & Co. Buy → Buy $12
2025-04-02 reit Citizens Capital Markets Market Outperform → Market Outperform $25
2025-03-14 reit Citizens Capital Markets Market Outperform → Market Outperform $25
2025-03-03 reit HC Wainwright & Co. Buy → Buy $12
2025-02-28 init William Blair — → Market Perform —
2025-02-05 reit HC Wainwright & Co. Buy → Buy $12
2025-01-23 reit HC Wainwright & Co. Buy → Buy $12
2025-01-22 reit HC Wainwright & Co. Buy → Buy $12
2025-01-08 init Stifel — → Buy $18
2024-11-14 reit HC Wainwright & Co. Buy → Buy $12
News
RSS: Latest ALT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-06 WEAVER GREGORY L Chief Financial Officer — 5,000 $3.54 $17,700
2026-03-06 DURSO JEROME BENEDICT Chief Executive Officer — 20,000 $3.54 $70,790
2026-02-02 ROBERTS M SCOT Officer — 17,050 — —
2026-01-30 JORDT RAYMOND M Officer — 4,571 $5.60 $25,598
2026-01-30 ROBERTS M SCOT Officer — 5,567 $5.60 $31,175
2026-01-30 GARG VIPIN K. Director — 6,926 $5.60 $38,786
2026-01-30 GARG VIPIN K. Director — 26,775 — —
2026-01-27 GARG VIPIN K. Director — 41,200 — —
2026-01-27 JORDT RAYMOND M Officer — 15,850 — —
2026-01-23 ROBERTS M SCOT Officer — 14,600 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.04
+105.00%
0.02
-95.31%
0.43
+726.47%
-0.07
Operating Revenue
0.04
+105.00%
0.02
-95.31%
0.43
+726.47%
-0.07
Operating Expense
94.53
-8.39%
103.19
+22.94%
83.94
-4.26%
87.67
Research And Development
66.43
-19.21%
82.23
+24.97%
65.80
-6.72%
70.54
Selling General And Administration
28.10
+34.02%
20.97
+15.60%
18.14
+5.85%
17.13
General And Administrative Expense
28.10
+34.02%
20.97
+15.60%
18.14
+5.85%
17.13
Other Gand A
28.10
+34.02%
20.97
+15.60%
18.14
+5.85%
17.13
Total Expenses
94.53
-8.39%
103.19
+22.94%
83.94
-4.26%
87.67
Operating Income
-94.49
+8.42%
-103.17
-23.54%
-83.51
+4.82%
-87.74
Total Operating Income As Reported
-94.49
+8.42%
-103.17
-7.55%
-95.93
-9.33%
-87.74
EBITDA
-87.03
+8.21%
-94.81
-7.82%
-87.94
-4.18%
-84.41
Normalized EBITDA
-87.03
+8.21%
-94.81
-25.55%
-75.52
+10.54%
-84.41
Reconciled Depreciation
0.11
-52.94%
0.24
-50.10%
0.48
-3.25%
0.49
EBIT
-87.14
+8.32%
-95.05
-7.51%
-88.41
-4.13%
-84.90
Total Unusual Items
—
0.00
+100.00%
-12.42
0.00
Total Unusual Items Excluding Goodwill
—
0.00
+100.00%
-12.42
0.00
Special Income Charges
—
0.00
+100.00%
-12.42
0.00
Impairment Of Capital Assets
—
0.00
-100.00%
12.42
0.00
Net Income
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Pretax Income
-88.77
+6.61%
-95.06
-7.48%
-88.45
-4.17%
-84.91
Net Non Operating Interest Income Expense
5.91
-26.78%
8.06
+10.24%
7.32
+155.63%
2.86
Interest Expense Non Operating
1.64
+18077.78%
0.01
-74.29%
0.04
+337.50%
0.01
Net Interest Income
5.91
-26.78%
8.06
+10.24%
7.32
+155.63%
2.86
Interest Expense
1.64
+18077.78%
0.01
-74.29%
0.04
+337.50%
0.01
Interest Income Non Operating
7.54
-6.60%
8.07
+9.84%
7.35
+156.13%
2.87
Interest Income
7.54
-6.60%
8.07
+9.84%
7.35
+156.13%
2.87
Other Income Expense
-0.19
-495.83%
0.05
+100.39%
-12.25
-38190.63%
-0.03
Other Non Operating Income Expenses
-0.19
-495.83%
0.05
-71.08%
0.17
+618.75%
-0.03
Tax Provision
-0.68
0.00
0.00
+100.00%
-0.20
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Net Income From Continuing Operation Net Minority Interest
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Net Income From Continuing And Discontinued Operation
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Net Income Continuous Operations
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Normalized Income
-88.09
+7.33%
-95.06
-25.03%
-76.03
+10.25%
-84.71
Net Income Common Stockholders
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Diluted EPS
-1.00
+25.37%
-1.34
+19.28%
-1.66
+8.29%
-1.81
Basic EPS
-1.00
+25.37%
-1.34
+19.28%
-1.66
+8.29%
-1.81
Basic Average Shares
88.10
+24.08%
71.00
+33.35%
53.25
+13.47%
46.93
Diluted Average Shares
88.10
+24.08%
71.00
+33.35%
53.25
+13.47%
46.93
Diluted NI Availto Com Stockholders
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Line Item Trend 2023-12-31
Total Assets
210.64
Current Assets
209.63
Cash Cash Equivalents And Short Term Investments
197.81
Cash And Cash Equivalents
135.12
Other Short Term Investments
62.70
Receivables
4.85
Accounts Receivable
1.11
Taxes Receivable
3.74
Prepaid Assets
—
Restricted Cash
0.04
Other Current Assets
6.92
Total Non Current Assets
1.01
Net PPE
0.65
Gross PPE
2.63
Accumulated Depreciation
-1.98
Properties
0.00
Machinery Furniture Equipment
0.54
Other Properties
0.34
Leases
1.75
Goodwill And Other Intangible Assets
0.00
Other Intangible Assets
—
Other Non Current Assets
0.36
Total Liabilities Net Minority Interest
16.54
Current Liabilities
12.14
Payables And Accrued Expenses
11.65
Payables
2.07
Accounts Payable
2.07
Current Accrued Expenses
9.58
Total Tax Payable
0.00
Current Debt And Capital Lease Obligation
0.50
Current Capital Lease Obligation
0.50
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
4.40
Long Term Debt And Capital Lease Obligation
0.17
Long Term Debt
—
Long Term Capital Lease Obligation
0.17
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Other Non Current Liabilities
4.22
Stockholders Equity
194.10
Common Stock Equity
194.10
Capital Stock
0.01
Common Stock
0.01
Share Issued
70.68
Ordinary Shares Number
70.68
Treasury Shares Number
0.00
Additional Paid In Capital
665.43
Retained Earnings
-466.33
Gains Losses Not Affecting Retained Earnings
-5.00
Other Equity Adjustments
-5.00
Total Equity Gross Minority Interest
194.10
Total Capitalization
194.10
Working Capital
197.48
Invested Capital
194.10
Total Debt
0.67
Capital Lease Obligations
0.67
Net Tangible Assets
194.10
Tangible Book Value
194.10
Interest Payable
0.12
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-67.53
+15.42%
-79.85
-5.33%
-75.81
-21.13%
-62.59
Cash Flow From Continuing Operating Activities
-67.53
+15.42%
-79.85
-5.33%
-75.81
-21.13%
-62.59
Net Income From Continuing Operations
-88.09
+7.33%
-95.06
-7.48%
-88.45
-4.41%
-84.71
Depreciation Amortization Depletion
0.11
-52.94%
0.24
-50.10%
0.48
-3.25%
0.49
Depreciation
0.11
-52.94%
0.24
-50.10%
0.48
-3.25%
0.49
Depreciation And Amortization
0.11
-52.94%
0.24
-50.10%
0.48
-3.25%
0.49
Other Non Cash Items
0.36
—
—
0.09
Stock Based Compensation
16.08
+11.69%
14.39
+35.27%
10.64
+31.34%
8.10
Asset Impairment Charge
—
0.00
-100.00%
12.42
0.00
Deferred Tax
-0.68
0.00
—
—
Deferred Income Tax
-0.68
0.00
—
—
Operating Gains Losses
0.16
+433.33%
-0.05
+68.83%
-0.15
-552.94%
0.03
Net Foreign Currency Exchange Gain Loss
0.16
+433.33%
-0.05
+68.83%
-0.15
-552.94%
0.03
Change In Working Capital
6.75
+50.78%
4.48
+154.12%
-8.27
-158.64%
14.11
Change In Receivables
2.06
+18.72%
1.74
+175.09%
-2.31
-170.10%
3.30
Changes In Account Receivables
-0.68
-219.05%
0.57
+160.45%
-0.94
-466.41%
0.26
Change In Prepaid Assets
-0.20
-104.33%
4.71
+450.41%
-1.34
-150.75%
2.65
Change In Payables And Accrued Expense
4.89
+348.35%
-1.97
+57.31%
-4.62
-156.56%
8.16
Change In Accrued Expense
2.39
+2233.04%
-0.11
+94.05%
-1.88
-134.92%
5.39
Change In Payable
2.51
+234.80%
-1.86
+32.00%
-2.73
-198.70%
2.77
Change In Account Payable
2.51
+234.80%
-1.86
+32.00%
-2.73
-198.70%
2.77
Investing Cash Flow
-132.47
-366.68%
-28.39
-306.71%
13.73
+118.71%
-73.40
Cash Flow From Continuing Investing Activities
-132.47
-366.68%
-28.39
-306.71%
13.73
+118.71%
-73.40
Net PPE Purchase And Sale
-0.01
0.00
+100.00%
-0.05
+62.70%
-0.13
Purchase Of PPE
-0.01
0.00
+100.00%
-0.05
+62.70%
-0.13
Capital Expenditure
-0.01
—
-0.05
+62.70%
-0.13
Net Investment Purchase And Sale
-132.46
-366.65%
-28.39
-306.01%
13.78
+118.81%
-73.27
Purchase Of Investment
-285.45
-146.65%
-115.73
-30.58%
-88.63
-20.96%
-73.27
Sale Of Investment
152.99
+75.15%
87.34
-14.71%
102.41
0.00
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Financing Cash Flow
206.84
+1959.36%
10.04
-88.34%
86.11
+51.64%
56.78
Cash Flow From Continuing Financing Activities
206.84
+1959.36%
10.04
-88.34%
86.11
+51.64%
56.78
Net Issuance Payments Of Debt
35.00
0.00
—
—
Issuance Of Debt
35.00
0.00
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
35.00
0.00
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
35.00
0.00
—
—
Net Common Stock Issuance
173.73
+1638.37%
9.99
-88.46%
86.60
+53.69%
56.35
Proceeds From Stock Option Exercised
0.33
-63.11%
0.90
+174.39%
0.33
-65.47%
0.95
Net Other Financing Charges
-2.22
-161.53%
-0.85
-3.16%
-0.82
-59.69%
-0.52
Changes In Cash
6.83
+106.96%
-98.19
-508.67%
24.03
+130.34%
-79.20
Beginning Cash Position
36.97
-72.65%
135.16
+21.62%
111.13
-41.61%
190.34
End Cash Position
43.80
+18.49%
36.97
-72.65%
135.16
+21.62%
111.13
Free Cash Flow
-67.55
+15.41%
-79.85
-5.26%
-75.86
-20.96%
-62.71
Interest Paid Supplemental Data
0.97
0.00
—
—
Amortization Of Securities
-2.22
+42.23%
-3.85
-55.81%
-2.47
-254.01%
-0.70
Common Stock Issuance
173.73
+1638.37%
9.99
-88.46%
86.60
+53.69%
56.35
Issuance Of Capital Stock
173.73
+1638.37%
9.99
-88.46%
86.60
+53.69%
56.35
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category